Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Led by computational researchers from WEHI, in collaboration with The University of Queensland, Queensland University of Technology and Hospital Marcelino Champagnat in Brazil, the study used advanced spatial transcriptomic techniques to screen for genes associated with excessive inflammation in the lungs, a key indicator of severe COVID-19.
In new studies, researchers concluded that licorice triterpenoids could be candidates for anti-SARS-CoV-2 drug developments.
Researchers investigate the potential value of a new vaccine candidate for the influenza virus.
Researchers have been exploring data from COVID-19 patients tested at hospitals or clinics that also look for evidence of other diseases.
A recent review article looks at the potential of nanotechnology in fighting severe acute respiratory syndrome 2 (SARS-CoV-2), with several possibilities of strategies in therapeutics, vaccines, and prevention.
A new study, published on the bioRxiv* preprint server, has discovered a class of new immunostimulatory RNAs while studying influenza infection-associated host genes in human lung epithelial cells using small interfering RNAs (siRNAs). Scientists revealed that these short duplex RNAs could induce type I and type III interferons (IFN-I/III) in a wide variety of cells.
A novel study is assessing whether medicinal mushrooms and Chinese herbs provide therapeutic benefit in treating acute COVID-19 infection.
A new study explores the role of arginylation during SARS-CoV-2 infection.
In the current study, SARS-CoV-2 antibodies were identified in over a third of free-ranging deer in northeast Ohio.
Researchers have tried to develop an innovative platform for ultrasensitive and rapid detection of SARS-CoV-2 by exploiting a variation of Raman Spectroscopy.
Researchers evaluate the safety and immunogenicity of an influenza vaccine and mRNA-based COVID-19 vaccine that were administered concomitantly.
German scientists used DNA nanolevers to target the interaction between a peptide known as PeB and influenza A.
A new review discusses how molecular and structural biology have contributed to our understanding of antibody recognition of HIV-1, SARS-CoV-2, and Zika.
Researchers emphasize that an effective vaccine should induce mucosal immunity and prevent the nasal entry of SARS-CoV-2.
A study exploring cross-cultural differences in knowledge and attitudes towards COVID-19 reveals that people in Europe had the least knowledge of COVID-19 and lowest tendency to care about the coronavirus, while people in the United States had the lowest tendency to comply with public health restrictions.
A multidisciplinary national research team led by University of Utah Health scientists has launched a comprehensive review and analysis of data collected about COVID-19 in hopes of improving the nation’s ability to predict, detect, and respond to future pandemics.
Researchers from Columbia University have been investigating the impact of the pandemic on the spread of non-coronavirus respiratory viral infections in New York.
The cruel impact of COVID-19, the virus that emerged in late 2019 and has claimed 5 million lives to date, is chronicled in daily headlines. It has robbed us of loved ones, jobs, plans and so much more.
The results of a phase 2 clinical trial featuring a SARS-CoV-2 recombinant protein vaccine developed by GlaxoSmithKline are reported, demonstrating a favorable immune response amongst both naïve and non-naïve adults with an acceptable safety profile.
With flu season approaching in the United States, new research from an international team of scientists testifies to the importance of timely vaccination